Nothing Special   »   [go: up one dir, main page]

BR112022012230A2 - Variantes de progranulina - Google Patents

Variantes de progranulina

Info

Publication number
BR112022012230A2
BR112022012230A2 BR112022012230A BR112022012230A BR112022012230A2 BR 112022012230 A2 BR112022012230 A2 BR 112022012230A2 BR 112022012230 A BR112022012230 A BR 112022012230A BR 112022012230 A BR112022012230 A BR 112022012230A BR 112022012230 A2 BR112022012230 A2 BR 112022012230A2
Authority
BR
Brazil
Prior art keywords
progranulin
variants
proteins
ftd
polypeptide
Prior art date
Application number
BR112022012230A
Other languages
English (en)
Inventor
Maxwell Cherf Gerald
Kannan Gunasekaran
W Lexa Katrina
L Y Low Ray
Prorok Rachel
Srivastava Ankita
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Priority claimed from PCT/US2020/066831 external-priority patent/WO2021133907A1/en
Publication of BR112022012230A2 publication Critical patent/BR112022012230A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

VARIANTES DE PROGRANULINA. A presente invenção refere-se a variantes de progranulina e proteínas de fusão que compreendem uma variante de progranulina e um polipeptídeo Fc. Métodos de uso de tais proteínas para tratar distúrbios associados à progranulina (por exemplo, uma doença neurodegenerativa, como demência frontotemporal (FTD)) também são fornecidos neste documento.
BR112022012230A 2019-12-23 2020-12-23 Variantes de progranulina BR112022012230A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953099P 2019-12-23 2019-12-23
US202063091819P 2020-10-14 2020-10-14
PCT/US2020/066831 WO2021133907A1 (en) 2019-12-23 2020-12-23 Progranulin variants

Publications (1)

Publication Number Publication Date
BR112022012230A2 true BR112022012230A2 (pt) 2022-08-30

Family

ID=76437806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012230A BR112022012230A2 (pt) 2019-12-23 2020-12-23 Variantes de progranulina

Country Status (12)

Country Link
US (4) US20210188925A1 (pt)
EP (1) EP4081536A1 (pt)
JP (1) JP2023507846A (pt)
KR (1) KR20220130678A (pt)
CN (1) CN114981297A (pt)
AU (1) AU2020411480B2 (pt)
BR (1) BR112022012230A2 (pt)
CA (1) CA3165846A1 (pt)
CO (1) CO2022008648A2 (pt)
IL (1) IL293994A (pt)
MX (1) MX2022007486A (pt)
PE (1) PE20230036A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
KR20200058510A (ko) 2017-10-02 2020-05-27 데날리 테라퓨틱스 인크. 효소 대체 요법 효소를 포함하는 융합 단백질
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
AU2021362209A1 (en) 2020-10-14 2023-05-18 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110938A1 (en) 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2002236499A8 (en) 2000-11-30 2009-12-03 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
CN102180944A (zh) 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050123962A1 (en) 2003-10-28 2005-06-09 Agy Therapeutics, Inc. Regulated nucleic acids in pathogenesis of alzheimer's disease
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
RS50752B (sr) 2005-01-05 2010-08-31 F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. Domeni sintetskih imunoglobulina sa svojstvima vezivanja, konstruisani u regionima molekula, koji se razlikuju od regiona, koji određuju komplementarnost
DK2687223T3 (en) 2006-05-30 2017-10-23 Mayo Foundation Detection and treatment of dementia
DK2037948T3 (en) 2006-05-30 2016-08-01 Mayo Foundation Detection and treatment of dementia
SI2029742T1 (sl) 2006-06-07 2016-11-30 Genzyme Corporation Genska terapija amiotrofične lateralne skleroze in drugih motenj hrbtenjače
WO2008094687A2 (en) 2007-01-31 2008-08-07 New York University Gep, a novel chondrogenic growth factor and target in cartilage disorders
DE102007033359B4 (de) 2007-07-16 2010-12-02 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN102724993B (zh) 2009-04-17 2016-04-27 纽约大学 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途
EP2640407A4 (en) 2010-11-16 2014-07-09 Denis G Kay PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
AU2011336716B2 (en) 2010-11-30 2016-01-21 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
AR085138A1 (es) 2011-02-04 2013-09-11 Genentech Inc VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013162050A1 (ja) 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
SG11201500583PA (en) 2012-08-29 2015-04-29 Hoffmann La Roche Blood brain barrier shuttle
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
CA3222990A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
MX2015015970A (es) 2013-05-20 2016-09-08 Genentech Inc Anticuerpos receptores de antitransferina y metodos de uso.
SG10201800982QA (en) 2013-07-05 2018-03-28 Genmab As Humanized or chimeric cd3 antibodies
CN113527512A (zh) 2013-07-31 2021-10-22 美国安进公司 生长分化因子15(gdf-15)构建体
WO2015024931A1 (en) 2013-08-19 2015-02-26 Moghimi Seyed Moien Peptidic nanodelivery composition targeting two receptors
AU2015214358A1 (en) 2014-02-04 2016-08-18 New York University Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
WO2016077840A2 (en) 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
CN107001473B (zh) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
PE20180602A1 (es) 2015-06-24 2018-04-09 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
BR112017027965A2 (pt) 2015-06-24 2018-08-28 Japan Chem Res anticorpo receptor, proteína de fusão, fragmento de dna, vetor de expressão, célula, complexo de anticorpo receptor, usos de um anticorpo receptor e de uma proteína de fusão, e, métodos para tratamento de um distúrbio e de uma doença.
EP3331356A4 (en) 2015-08-04 2019-04-10 New York University PROGRANULIN (PGRN) FRAGMENTS AND DERIVATIVES FOR THE TREATMENT OR AID OF LYSOSOMAL STORAGE DISEASES
AU2016323440B2 (en) 2015-09-15 2023-07-13 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US20210284701A1 (en) 2016-07-14 2021-09-16 Emory University Granulin Compositions and Uses Related Thereto
NZ752703A (en) 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
RS64584B1 (sr) 2017-08-10 2023-10-31 Denali Therapeutics Inc Konstruisani polipeptidi koji se vezuju za transferinski receptor
KR20200058510A (ko) 2017-10-02 2020-05-27 데날리 테라퓨틱스 인크. 효소 대체 요법 효소를 포함하는 융합 단백질
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
SG11202006420TA (en) 2018-01-10 2020-08-28 Denali Therapeutics Inc Transferrin receptor-binding polypeptides and uses thereof
KR102204521B1 (ko) 2018-04-17 2021-01-20 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
KR20210027377A (ko) 2018-06-18 2021-03-10 데날리 테라퓨틱스 인크. 프로그래뉼린을 포함하는 융합 단백질
MA53616A (fr) 2018-08-16 2022-05-04 Denali Therapeutics Inc Protéines bispécifiques modifiées
AU2019326545A1 (en) 2018-08-22 2021-03-11 Denali Therapeutics Inc. Anti-HER2 polypeptides and methods of use thereof
CA3115345A1 (en) 2018-10-16 2020-04-23 Denali Therapeutics Inc. Methods for treating and monitoring progranulin-associated disorders
WO2020123511A2 (en) 2018-12-10 2020-06-18 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
KR20220004651A (ko) 2019-04-03 2022-01-11 데날리 테라퓨틱스 인크. 이두로네이트 2-설파타제를 포함하는 단백질 분자의 제제
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
MX2022008582A (es) 2020-01-13 2022-08-10 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos.
US20230092681A1 (en) 2020-02-07 2023-03-23 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
AU2021362209A1 (en) 2020-10-14 2023-05-18 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
AU2021362487A1 (en) 2020-10-14 2023-06-08 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia

Also Published As

Publication number Publication date
CO2022008648A2 (es) 2022-06-30
IL293994A (en) 2022-08-01
CA3165846A1 (en) 2021-07-01
US20210188925A1 (en) 2021-06-24
CN114981297A (zh) 2022-08-30
PE20230036A1 (es) 2023-01-10
US20220213155A1 (en) 2022-07-07
KR20220130678A (ko) 2022-09-27
AU2020411480A1 (en) 2022-06-30
EP4081536A1 (en) 2022-11-02
MX2022007486A (es) 2022-06-29
US11643446B2 (en) 2023-05-09
US20220220172A1 (en) 2022-07-14
US20230265137A1 (en) 2023-08-24
JP2023507846A (ja) 2023-02-27
AU2020411480B2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
BR112022012230A2 (pt) Variantes de progranulina
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
BR112018011308A2 (pt) anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
MX2020007628A (es) Composiciones y metodos de uso.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
EA201691834A1 (ru) Новый способ очистки гонадотропина
CL2019000702A1 (es) Anticuerpos anti-gm-csf y usos de los mismos.
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
ECSP22049014A (es) Variantes de progranulina
CL2020002507A1 (es) Variantes de lfa3 y composiciones y usos de las mismas
AR115565A1 (es) Proteínas de fusión que comprenden progranulina
BR112022014160A2 (pt) Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau
EA202190062A1 (ru) Слитые белки, содержащие програнулин
AR119984A1 (es) Proteínas de fusión nkg2d y sus usos
AR119587A1 (es) Composiciones biofarmacéuticas y procedimientos conexos
EA202092327A1 (ru) Варианты lfa3 и их композиции и применение